MRK · Merck & Co Inc.
AI read · Bad for MRK
The AI's read
Trump signed an executive order narrowing core childhood vaccine recommendations to 11 and ordered HHS to pursue single-vaccine options and stronger safety monitoring. That directly calls out vaccines made by Merck, GSK, and Sanofi and targets M‑M‑R II and ProQuad. On the face of it this raises policy and demand risk for Merck's vaccine franchise. The stock is already up +1.8% on the headline and RSI reads 82.59, so near-term strength looks priced in. We lean bearish on MRK's vaccine revenue risk because school mandates, exemptions, and safety reviews could reduce uptake. The market rally cuts conviction, so this is a policy-risk play that needs cautious sizing and timing.